Hasil Pencarian - B. Douglas Smith

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis

    Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis oleh Jose Tinajero, Khaled El-Shami, Xiaojun Wu, B. Douglas Smith, Matthew J. Newman

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS

    PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS oleh Susanne Isfort, Carlo Gambacorti-Passerini, Tim H Brümmendorf, B. Douglas Smith, Simon Purcell, Huadong Zhao, Luke Kuttschreuter, Jane Apperley

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

    P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES oleh Keith Pratz, Courtney Dinardo, Martha L Arellano, Michael Thirman, Vinod Pullarkat, Pamela S. Becker, B. Douglas Smith, Meng Zhang, Michael E Werner, Jalaja Potluri, Daniel A. Pollyea

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

    A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML oleh Alexander J. Ambinder, Kelly Norsworthy, Daniela Hernandez, Laura Palau, Bogdan Paun, Amy Duffield, Rosh Chandraratna, Martin Sanders, Ravi Varadhan, Richard J. Jones, B. Douglas Smith, Gabriel Ghiaur

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes

    Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes oleh Jonathan M. Gerber, Joshua F. Zeidner, Sarah Morse, Amanda L. Blackford, Brandy Perkins, Breann Yanagisawa, Hao Zhang, Laura Morsberger, Judith Karp, Yi Ning, Christopher D. Gocke, Gary L. Rosner, B. Douglas Smith, Richard J. Jones

    Diterbitkan 2016-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms oleh Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Diterbitkan 2014-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

    Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy oleh Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

    Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation oleh Sergiu Pasca, Saurav D. Haldar, Alexander Ambinder, Jonathan A. Webster, Tania Jain, W. Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, B. Douglas Smith, Theodoros Karantanos, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy

    Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy oleh Meghali Goswami, Gabrielle Prince, Angelique Biancotto, Susan Moir, Lela Kardava, Brian H. Santich, Foo Cheung, Yuri Kotliarov, Jinguo Chen, Rongye Shi, Huizhi Zhou, Hana Golding, Jody Manischewitz, Lisa King, Lauren M. Kunz, Kimberly Noonan, Ivan M. Borrello, B. Douglas Smith, Christopher S. Hourigan

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

    Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemi... oleh Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher D. Gocke, Gary L. Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith, Judith E. Karp

    Diterbitkan 2015-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

    Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia oleh Scott H. Kaufmann, Judith E. Karp, Mark R. Litzow, Ruben A. Mesa, William Hogan, David P. Steensma, Karen S. Flatten, David A. Loegering, Paula A. Schneider, Kevin L. Peterson, Matthew J. Maurer, B. Douglas Smith, Jacqueline Greer, Yuhong Chen, Joel M. Reid, S. Percy Ivy, Matthew M. Ames, Alex A. Adjei, Charles Erlichman, Larry M. Karnitz

    Diterbitkan 2011-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

    Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk a... oleh Judith E. Karp, Elizabeth Garrett-Mayer, Elihu H. Estey, Michelle A. Rudek, B. Douglas Smith, Jacqueline M. Greer, D. Michelle Drye, Karen Mackey, Kathleen Shannon Dorcy, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle, John J. Wright, John M. Pagel

    Diterbitkan 2012-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Increased body mass index is a risk factor for acute promyelocytic leukemia

    Increased body mass index is a risk factor for acute promyelocytic leukemia oleh Sarah M. Kashanian, Andrew Y. Li, Moaath Mustafa Ali, Mark E. Sutherland, Vu H. Duong, Bryan C. Hambley, Kyle Zacholski, Firas El Chaer, Noa G. Holtzman, Mohammad Imran, Ciera L. Patzke, Jonathan Cornu, Alison Duffy, Amy E. Dezern, Ivana Gojo, Kelly J. Norsworthy, Mark J. Levis, B. Douglas Smith, Maria R. Baer, Gabriel Ghiaur, Ashkan Emadi

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

    A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia oleh Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

    Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide oleh Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry, Javier Bolaños-Meade, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, Ivana Gojo, B. Douglas Smith, Maria P. Bettinotti, William H. Matsui, Amy E. Dezern, Carol Ann Huff, Ivan Borrello, Keith W. Pratz, Douglas E. Gladstone, Lode J. Swinnen, Robert A. Brodsky, Mark J. Levis, Richard F. Ambinder, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik

    Diterbitkan 2017-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: